News provided by Ro Dec 10, 2025, 09:00 ET Peer-reviewed study demonstrates patients treated with semaglutide through Ro achieve an average body weight loss of 16.6% over 68 weeks First study to evaluate both the long-term weight loss and safety outcomes of treatment with semaglutide via telehealth NEW YORK, Dec
Planning for years rather than months means investing in the meal pattern, the training routine, and the lab monitoring system that supports decades of sustainable use
From a pharmacokinetic perspective, semaglutide is administered subcutaneously once weekly and is primarily degraded by proteolytic enzymes rather than being metabolised by the liver's cytochrome P450 enzyme system
Electrolyte monitoring is not routinely required for all GLP-1 users, but becomes essential when patients experience persistent gastrointestinal symptoms or have additional risk factors such as chronic kidney disease, heart failure, age over 65, or concurrent diuretic use
Administering the initial dosage under medical supervision is advisable to monitor any potential reactions
Practical next steps clinicians typically recommend include checking blood sugar control, testing vaginal discharge to distinguish yeast from bacterial vaginosis or other causes, treating confirmed Candida with topical or oral antifungals, and addressing contributing factors such as dehydration, antibiotic use, or changes in estrogen status
/assets/production/practices/8374cadb2253e5496cfee3ef82ab5175a5e6343b/images/2820189.png)
